In silico evidence of beauvericin antiviral activity against SARS-CoV-2.

ABSTRACT:

Background

Scientists are still battling severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus 2019 (COVID-19) pandemic so human lives can be saved worldwide. Secondary fungal metabolites are of intense interest due to their broad range of pharmaceutical properties. Beauvericin (BEA) is a secondary metabolite produced by the fungus Beauveria bassiana. Although promising anti-viral activity has previously been reported for BEA, studies investigating its therapeutic potential are limited.

Methods

The objective of this study was to assess the potential usage of BEA as an anti-viral molecule via protein-protein docking approaches using MolSoft.

Results

In-silico results revealed relatively favorable binding energies for BE

SUBMITTER: Al Khoury C 

PROVIDER: S-EPMC8709726 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature